By Fineline Cube 
Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration business for approximately USD 4.1 billion in cash, expanding its capabilities in biologics production and industrial filtration.
Business Profile
Solventum’s unit is a global leader in purification and filtration technologies, serving biologics manufacturing, medical tech, and industrial sectors. It operates across the Americas, Europe, Middle East, Africa, and Asia-Pacific, with a workforce of 2,500. The business generated USD 1 billion in revenue in 2024.
Strategic Fit
The acquisition will bolster Thermo Fisher’s life sciences portfolio, integrating advanced filtration solutions into its existing offerings. The deal underscores Thermo Fisher’s strategy to strengthen its position in high-growth markets.-Fineline Info & Tech